STRO · XBRL financial data

Sutro Biopharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (STRO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	17	year only	13	26	9	15*	17	64	10	12*	15	10
Research and development	46	54*	57	62	62	71*	52	38	40	37*	37	32
General and administrative	15	17*	13	12	14	9*	13	10	9	9*	8	8
Total operating expenses	61	71*	70	74	76	80*	86	67	58	50*	44	40
Operating income (loss)	(44)	43*	(57)	(49)	(68)	(65)*	(69)	(3)	(48)	(38)*	(30)	(30)
Interest expense	0	0*	—	—	—	—	—	—	—	—	—	—
Income tax expense (benefit)	2	16*	—	0	0	2*	0	(0)	0	(0)*	(0)	0
Net income (loss)	(49)	31*	(58)	(48)	(49)	(72)*	(76)	(11)	(57)	(47)*	(38)	(39)
Earnings per share, basic‡ USD per share	(8.10)	5.10*	(9.50)	(5.90)	(5.90)	(8.80)*	(9.10)	(1.40)	(6.70)	(5.36)*	(2.94)	(2.33)
Earnings per share, diluted‡ USD per share	(8.10)	5.10*	(9.50)	(5.90)	(5.90)	(8.80)*	(9.10)	(1.40)	(6.70)	(5.36)*	(2.94)	(2.33)
Weighted average shares, basic‡ millions of shares	6	6*	6	8	8	8*	8	8	8	9*	13	17
Weighted average shares, diluted‡ millions of shares	6	6*	6	8	8	8*	8	8	8	9*	13	17

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (STRO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	82	69	65	91	175	190	106	64	66	58	74	54
Marketable securities	239	264	202	285	214	127	143	141	102	83	129	110
Marketable securities, non-current	—	0	0	0	0	0	0	0	0	0	0	0
Accounts receivable	17	36	31	7	7	9	14	8	4	4	12	6
Prepaid and other current assets	9	10	10	11	11	18	25	19	11	6	6	6
Total current assets	381	422	355	443	406	343	287	232	182	151	221	176
Property and equipment, net	22	22	21	19	19	18	17	15	13	11	9	8
Right-of-use asset	24	23	22	20	19	18	16	15	13	11	10	8
Total assets	432	471	403	489	452	387	321	262	210	174	242	194
Accounts payable	6	9	8	6	6	10	8	4	7	8	5	3
Accrued liabilities	11	15	7	10	13	13	12	12	13	15	5	6
Current portion of long-term debt	—	4	—	—	—	—	—	—	—	—	—	—
Total current liabilities	74	94	80	130	131	132	133	74	72	75	71	53
Long-term debt	—	0	—	—	—	—	—	—	—	—	—	—
Lease liability, non-current	25	23	21	20	18	16	14	12	10	8	6	4
Total liabilities	319	321	305	337	341	343	347	294	297	306	309	298
Accumulated deficit	(590)	(559)	(618)	(666)	(714)	(787)	(863)	(874)	(931)	(978)	(1,016)	(1,055)
Total stockholders' equity	112	150	98	152	111	45	(26)	(32)	(87)	(132)	(67)	(103)
Total liabilities and equity	432	471	403	489	452	387	321	262	210	174	242	194
Common shares outstanding (cover page)‡ millions of shares	6	6	8	8	8	8	8	8	9	17	17	17

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (STRO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(49)	31*	(58)	(48)	(49)	(72)*	(76)	(11)	(57)	(47)*	(38)	(39)
Stock-based compensation	6*	6*	6	6*	7*	6*	6	5*	2*	2*	2	2*
Depreciation and amortization	2*	2*	2	2*	2*	2*	2	2*	2*	2*	1	1*
Net cash from operating activities	(34)*	14*	(65)	9*	(65)*	(72)*	(68)	(45)*	(38)*	(26)*	(42)	(38)*
Net cash from investing activities	(114)*	(24)*	64	(80)*	147*	87*	(16)	3*	40*	19*	(45)	19*
Proceeds from issuing common stock	—	year only	—	—	0*	0*	—	—	0*	0*	—	—
Net cash from financing activities	(6)*	(3)*	(3)	96*	1*	(0)*	0	(0)*	0*	(0)*	103	(0)*
Net change in cash	(153)*	(13)*	(4)	26*	84*	16*	(84)	(42)*	2*	(8)*	16	(19)*

† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Sutro Biopharma	54	9.8	(38)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5.6	not reported	(2.8)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25	0.5	(1.9)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56	0*	(6.2)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Lifevantage	15	42*	4.8*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	24	not reported	(5.5)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85	0	(15)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85	not reported	(20)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Mersana Therapeutics	56	11	(3.2)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.